ProKidney Corp. Class A Ordinary Shares
PROK Real Time Price USDRecent trades of PROK by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PROK's directors and management
Government lobbying spending instances
-
$60,000 Apr 22, 2024 Issue: Health Issues
-
$60,000 Jan 19, 2024 Issue: Health Issues
-
$60,000 Oct 20, 2023 Issue: Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Bioactive renal cells for the treatment of chronic kidney disease Mar. 19, 2024
-
Patent Title: Renal cell populations and uses thereof Jun. 28, 2022
-
Patent Title: Bioactive renal cells for the treatment of chronic kidney disease Sep. 21, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of PROK in WallStreetBets Daily Discussion
Recent insights relating to PROK
Recent picks made for PROK stock on CNBC
ETFs with the largest estimated holdings in PROK
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PROK Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.